EntreMed's Next Generation Angiogenesis Inhibitors Highlighted At AACR Annual Meeting
ROCKVILLE, Md., April 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a biopharmaceutical leader in angiogenic research and product development, will present new findings on its strong angiogenic-based pipeline of next generation drug candidates throughout the American Association for Cancer Research (AACR) Annual Meeting in San Francisco. EntreMed's scientific team, including collaborators, will present 14 different abstracts covering three drug classes -- proteins, small molecules and vaccines. In addition to posters on EntreMed's three clinical drug candidates, Endostatin, Panzem(TM) and Angiostatin, EntreMed scientists will present data on the Company's angiogenic research pipeline, including tissue factor pathway inhibitors, hepatocyte growth factors, thalidomide analogs and growth factor vaccines.
(Photo: newscom.com )
Dr. Ed Gubish, EntreMed President and COO, commented, "The AACR meeting is a showcase for EntreMed's rich product pipeline and is a platform to share EntreMed's knowledge about diverse approaches to stopping abnormal blood vessel growth associated with over 80 diseases. EntreMed's commitment to the field of angiogenesis, along with our strong research expertise, enables our scientists to discover novel angiogenesis inhibitors from different drug classes, while maintaining our core focus on oncology product development." Dr. Gubish added, "The full impact of interrupting the angiogenesis cascade as a tool for disease management is still under appreciated. It is through forums such as the AACR meeting that translational research can guide clinical strategies in this emerging field."
Presentations on EntreMed's next-generation drug candidates at the AACR meeting include:
* A small fragment of tissue factor pathway inhibitor (TFPI) inhibits
tumor growth by more than 50% in preclinical models. Further, the
mechanism of action was identified and was mediated by very low- density lipoprotein receptors.
* Hepatocyte growth factor (HGF) fragments (K2-3 and NK1-3) inhibit
the growth of tumors and metastases in tumor models by effectively
blocking endothelial as well as tumor cells from spreading and
dividing.
* ENMD-0995, a new analog of thalidomide and a lead molecule in a
large candidate group that have been synthesized and patented by
EntreMed, demonstrates activity in preclinical models against B-cell
tumors, including Multiple Myeloma, and solid tumors in animal
models.
* A newly developed vaccine that targets a stimulator of tumor growth
and progression, basic fibroblast growth factor, does not alter
wound healing or reproductive capability in preclinical toxicology
studies.
To review these and additional EntreMed posters presented at the AACR meeting, please visit entremed.com .
The American Association for Cancer Research Annual Meeting is the largest multidisciplinary gathering in the world featuring cutting-edge developments in basic, translational and clinical cancer research. More than 13,000 cancer researchers, survivors, advocates and others concerned about cancer are expected to attend the five-day meeting that will highlight new research findings from more than 6,000 proffered scientific papers.
EntreMed, Inc., The Angiogenesis Company(R), is a clinical-stage biopharmaceutical company developing angiogenic therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with pharmaceutical and biotechnology companies, universities and government laboratories. EntreMed has a rich pipeline of new proteins, genes and small molecules. For further information, visit EntreMed's web site at entremed.com .
EntreMed's majority owned subsidiary, MaxCyte, Inc., develops targeted therapeutic products to treat severe and chronic diseases, including cancer, serious infections, cardiovascular disease and genetic disorders, based on its proprietary technology that uses blood cells for drug and non-viral gene delivery. For further information, please visit maxcyte.com .
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CONTACT: Amy Finan, Director, Corporate Communications & Industry Relations, of EntreMed, Inc., +1-240-413-3300, or +1-240-864-2640.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE EntreMed, Inc.
CO: EntreMed, Inc.; American Association for Cancer Research; AACR; MaxCyte, Inc.
ST: Maryland, California
IN: BIO MTC
SU:
04/06/2002 09:00 EST prnewswire.com |
